IBDEI1JN ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27412,2)
 ;;=^269618
 ;;^UTILITY(U,$J,358.3,27413,0)
 ;;=404.11^^162^1781^30
 ;;^UTILITY(U,$J,358.3,27413,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27413,1,4,0)
 ;;=4^404.11
 ;;^UTILITY(U,$J,358.3,27413,1,5,0)
 ;;=5^HTN w/ CHF & CKD I-IV/Unspec
 ;;^UTILITY(U,$J,358.3,27413,2)
 ;;=^269619
 ;;^UTILITY(U,$J,358.3,27414,0)
 ;;=404.12^^162^1781^35
 ;;^UTILITY(U,$J,358.3,27414,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27414,1,4,0)
 ;;=4^404.12
 ;;^UTILITY(U,$J,358.3,27414,1,5,0)
 ;;=5^HTN w/ Heart Involvement & CKD V/ESRD
 ;;^UTILITY(U,$J,358.3,27414,2)
 ;;=^269620
 ;;^UTILITY(U,$J,358.3,27415,0)
 ;;=404.13^^162^1781^31
 ;;^UTILITY(U,$J,358.3,27415,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27415,1,4,0)
 ;;=4^404.13
 ;;^UTILITY(U,$J,358.3,27415,1,5,0)
 ;;=5^HTN w/ CHF & CKD V/ESRD
 ;;^UTILITY(U,$J,358.3,27415,2)
 ;;=^269621
 ;;^UTILITY(U,$J,358.3,27416,0)
 ;;=401.9^^162^1781^55
 ;;^UTILITY(U,$J,358.3,27416,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27416,1,4,0)
 ;;=4^401.9
 ;;^UTILITY(U,$J,358.3,27416,1,5,0)
 ;;=5^Hypertension, Unspec
 ;;^UTILITY(U,$J,358.3,27416,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,27417,0)
 ;;=272.0^^162^1781^53
 ;;^UTILITY(U,$J,358.3,27417,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27417,1,4,0)
 ;;=4^272.0
 ;;^UTILITY(U,$J,358.3,27417,1,5,0)
 ;;=5^Hypercholesterolemia, Pure
 ;;^UTILITY(U,$J,358.3,27417,2)
 ;;=^59973
 ;;^UTILITY(U,$J,358.3,27418,0)
 ;;=272.1^^162^1781^56
 ;;^UTILITY(U,$J,358.3,27418,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27418,1,4,0)
 ;;=4^272.1
 ;;^UTILITY(U,$J,358.3,27418,1,5,0)
 ;;=5^Hypertriglyceridemia
 ;;^UTILITY(U,$J,358.3,27418,2)
 ;;=Hypertriglyceridemia^101303
 ;;^UTILITY(U,$J,358.3,27419,0)
 ;;=272.2^^162^1781^61
 ;;^UTILITY(U,$J,358.3,27419,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27419,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,27419,1,5,0)
 ;;=5^Mixed Hyperlipidemia
 ;;^UTILITY(U,$J,358.3,27419,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,27420,0)
 ;;=454.0^^162^1781^83
 ;;^UTILITY(U,$J,358.3,27420,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27420,1,4,0)
 ;;=4^454.0
 ;;^UTILITY(U,$J,358.3,27420,1,5,0)
 ;;=5^Vericose Veins
 ;;^UTILITY(U,$J,358.3,27420,2)
 ;;=Vericose Veins^125410
 ;;^UTILITY(U,$J,358.3,27421,0)
 ;;=454.2^^162^1781^84
 ;;^UTILITY(U,$J,358.3,27421,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27421,1,4,0)
 ;;=4^454.2
 ;;^UTILITY(U,$J,358.3,27421,1,5,0)
 ;;=5^Vericose Veins w/ Ulcer&Inflammation
 ;;^UTILITY(U,$J,358.3,27421,2)
 ;;=^269821
 ;;^UTILITY(U,$J,358.3,27422,0)
 ;;=396.0^^162^1781^7
 ;;^UTILITY(U,$J,358.3,27422,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27422,1,4,0)
 ;;=4^396.0
 ;;^UTILITY(U,$J,358.3,27422,1,5,0)
 ;;=5^Aortic And Mitral Valve Stenosis
 ;;^UTILITY(U,$J,358.3,27422,2)
 ;;=Aortic and Mitral Stenosis^269580
 ;;^UTILITY(U,$J,358.3,27423,0)
 ;;=414.02^^162^1781^16
 ;;^UTILITY(U,$J,358.3,27423,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27423,1,4,0)
 ;;=4^414.02
 ;;^UTILITY(U,$J,358.3,27423,1,5,0)
 ;;=5^CAD, Occlusion Of Venous Graft
 ;;^UTILITY(U,$J,358.3,27423,2)
 ;;=CAD, Occlusion of Venous Graft^303282
 ;;^UTILITY(U,$J,358.3,27424,0)
 ;;=459.10^^162^1781^70
 ;;^UTILITY(U,$J,358.3,27424,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27424,1,4,0)
 ;;=4^459.10
 ;;^UTILITY(U,$J,358.3,27424,1,5,0)
 ;;=5^Post Phlebotic Syndrome
 ;;^UTILITY(U,$J,358.3,27424,2)
 ;;=Post Phlebotic Syndrome^328597
 ;;^UTILITY(U,$J,358.3,27425,0)
 ;;=428.20^^162^1781^50
 ;;^UTILITY(U,$J,358.3,27425,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27425,1,4,0)
 ;;=4^428.20
 ;;^UTILITY(U,$J,358.3,27425,1,5,0)
 ;;=5^Heart Failure, Systolic, Unspec
 ;;
 ;;$END ROU IBDEI1JN
